Use of the ExVent Accessory With the O2Vent Optima Oral Appliance for the Treatment of Obstructive Sleep Apnea

Centre for Sleep and Chronobiology, Canada

Status

Enrolling

Conditions

Sleep Apnea, Obstructive

Sleep-Disordered Breathing

Treatments

Device: ExVent

Study type

Interventional

Funder types

Other

Identifiers

NCT05954026

OVEN-02

Details and patient eligibility

About

The ExVent is an optional accessory to the O2Vent Optima MAD and provides oral Expiratory Positive Airway Pressure (EPAP). Oral EPAP with the ExVent is designed to provide upper airway support via similar mechanisms of action of nasal EPAP devices in commercial distribution, e.g., passive dilatation of the airway, which reduces flow limitation. Nasal EPAP devices are in commercial distribution as stand-alone therapies for the treatment of OSA. The oral EPAP provided by the ExVent accessory is designed to augment the OSA therapy provided by the O2Vent Optima.

Full description

Title Use of the ExVent Accessory with the O2Vent Optima Oral Appliance for the Treatment of Obstructive Sleep Apnea

Investigational Device Oventus Medical ExVent Accessory (inserted into the O2Vent Optima device)

Investigator Study Sites Up to 3 investigational sites

Regulatory Status This is a non-significant risk investigational device exemption (IDE) clinical trial. FDA approval is not required, but IRB review and approval are required.

Study Design Prospective, open label, single-arm multicenter study Sample Size Up to thirty (30) subjects will be enrolled to yield a minimum of 20 evaluable subjects (mITT subjects).

Study Objective To demonstrate that the ExVent Accessory (inserted into the O2Vent Optima device) is safe and effective in treating mild to moderate OSA Patient Population Patients who have been diagnosed with mild to moderate OSA (i.e., AHI ≥ 5 and ≤ 30)

Study Overview Study Design/ Duration:

This is a prospective, open-label, single-arm study conducted at up to 3 sites. Site participation is expected to be approximately 6 months from first subject enrollment until completion of the last study visit.

Screening Phase

Confirm subject meets all inclusion and exclusion criteria
In the absence of a prior diagnostic PSG study within the last 6 months at the investigational site's sleep lab, subject will complete a PSG study to obtain the baseline AHI and confirm a diagnosis of mild to moderate OSA

Home Use Phase

Subject uses the O2Vent Optima + ExVent for up to 3 months and logs usage hours.

PSG Night Subjects who successfully complete* the Home Use Phase will have an in-lab PSG sleep night while using the O2Vent Optima + ExVent

Primary Effectiveness Outcome Measure Change in AHI between baseline AHI and the AHI measured during the in-lab PSG sleep night using the O2Vent Optima + ExVent.

Primary Effectiveness Endpoint Statistically significant change in AHI with use of the O2Vent Optima + ExVent compared to baseline AHI value (i.e., no treatment).

Safety Outcome Measure Adverse events will be summarized descriptively in terms of type and frequency

Statistical Analysis This clinical trial is designed to determine whether the concomitant use of the O2Vent + ExVent devices results in a statistically significant reduction in AHI from the baseline value for each subject. A paired t-test will be used for this comparison.

A sample size calculation is based on data from a comparable group of patients (Lai, 2019), where it was determined that the mean change in AHI from baseline was -8.37, with a standard deviation of the paired differences of 7.73.

Setting alpha=0.05 and power=0.80, the calculated sample size is 9 subjects. Because of the imperfect predictability of historical data, to ensure adequate power this study will enroll 20 evaluable patients.

The mITT population will be used for this analysis**

Enrollment

20 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subject aged 22 years or older.
Subject completed a PSG study within the last 6 months at the investigational site's sleep lab and obtained a baseline AHI confirming a diagnosis of mild to moderate obstructive sleep apnea.
Subject (self-reports) that he/she is currently a compliant O2Vent Optima user (i.e., using the device for at least 4 hours/night for at least 5 nights/week).
Subject completed initial fitting optimization of the O2Vent Optima device.
Investigator has determined that the subject could abstain from use of the oral appliance or other sleep apnea therapies for up to 7 days.
Must be able to comply with all study requirements as outlined in the protocol.

Exclusion criteria

Inclusion Criteria:

Male or female subject aged 22 years or older.
Subject completed a PSG study within the last 6 months at the investigational site's sleep lab and obtained a baseline AHI confirming a diagnosis of mild to moderate obstructive sleep apnea.
Subject (self-reports) that he/she is currently a compliant O2Vent Optima user (i.e., using the device for at least 4 hours/night for at least 5 nights/week).
Subject completed initial fitting optimization of the O2Vent Optima device.
Investigator has determined that the subject could abstain from use of the oral appliance or other sleep apnea therapies for up to 7 days.
Must be able to comply with all study requirements as outlined in the protocol.

Exclusion Criteria:

Oral cavity infection or any other oral or dental condition or problem that would limit patient use of the O2Vent Optima oral appliance.
Any concomitant diagnosed or suspected sleep disorder including insomnia or central apnea.
History of any prior OSA surgical treatments including RF ablation treatment or palatal stent devices.
Concomitant use of any other prescription device for treatment of OSA.
Female of child-bearing age who is pregnant or intending to become pregnant during the study participation period.
Subject with significant change in weight since completion of the diagnostic baseline PSG study (i.e., ±10% or greater change in total body weight.
Subject on a non-stable dose of medications or other agents that may affect sleep and/or PSG (e.g., sedatives or hypnotics).
Subject who consumes > 500 mg caffeine per day (e.g., > 8 cola-type beverages, > 5 cups of coffee).
Subject who consumes > 3 alcoholic drinks/day.
Subject currently enrolled in any other research study.